International Journal of Pharma Insight Studies

Drug Repurposing for Novel Indications

Dr. Ramesh Kumar
School of Pharmacology, National Institute of Medical Research, Delhi, India

* Corresponding Author: **Dr. Ramesh Kumar**

Article Info

Volume: 01
Issue: 01
January-February 2024
Received: 01-01-2024
Accepted: 19-02-2024
Page No: 09-12

Abstract
Drug repurposing, also known as drug repositioning, is a strategy that identifies new therapeutic uses for existing drugs. This approach offers a cost-effective and time-efficient alternative to traditional drug discovery, leveraging existing safety and pharmacokinetic data. This article explores the concept of drug repurposing, its methodologies, and its potential in addressing unmet medical needs. We discuss various strategies, including computational approaches, experimental screening, and observational studies, and highlight successful examples of repurposed drugs. The article also addresses challenges and future directions in the field, emphasizing the importance of collaborative efforts and innovative technologies.

Keywords: Drug repurposing, drug repositioning, novel indications, computational approaches, experimental screening, observational studies, collaborative efforts

Introduction

The traditional drug discovery process is time-consuming, expensive, and fraught with high failure rates. It typically takes over a decade and billions of dollars to bring a new drug to market, with a success rate of less than 10% for compounds entering clinical trials. In contrast, drug repurposing offers a promising alternative by identifying new therapeutic uses for existing drugs, thereby reducing development time and costs. This strategy is particularly valuable in addressing unmet medical needs, such as rare diseases, antimicrobial resistance, and emerging infectious diseases.

Drug repurposing leverages existing knowledge about a drug's safety, pharmacokinetics, and pharmacodynamics, allowing for a more streamlined development process. This approach has gained significant attention in recent years, driven by advances in computational biology, high-throughput screening, and data mining techniques. Moreover, the COVID-19 pandemic has underscored the potential of drug repurposing in rapidly identifying treatments for emerging diseases.

This article provides a comprehensive overview of drug repurposing, including its methodologies, successes, challenges, and future directions. We aim to highlight the potential of this strategy in transforming drug discovery and improving patient outcomes.

Materials and Methods

1. Computational Approaches

Here’s how bioinformatics and data mining are commonly applied in drug repurposing:

1. **Gene Expression Data Analysis**: By analyzing gene expression profiles from drug-treated cells, bioinformatics tools can help identify which biological pathways are affected. This can suggest which diseases a drug might be effective against.
2. **Drug-Target Interaction Networks**: Data mining approaches can be used to map the interactions between known drugs and their molecular targets. These networks can be expanded to include possible interactions with other biological pathways, leading to new therapeutic indications.
3. **Repurposing Databases**: There are specialized databases, such as DrugBank or the Repurposing Drugs for Alzheimer's Disease (ReDO) project, which compile information about approved drugs and their potential to treat other conditions. Bioinformatics tools can extract and analyze data from these databases.
4. **Machine Learning and Predictive Modeling**: Machine learning algorithms can be applied to large datasets to predict which drugs might be effective for diseases they were not originally intended to treat. These models often use data from genomic, proteomic, and clinical studies.

5. **Clinical Data Mining**: Mining clinical trial data can uncover unforeseen effects of drugs, enabling their repurposing for different diseases.

Network Pharmacology

1. Drug-Target Network Construction

- Drugs rarely act on a single target. Instead, they may interact with multiple proteins, enzymes, receptors, or other molecules. Network pharmacology constructs drug-target interaction networks to predict which drug might be effective for a disease based on its ability to influence a variety of targets involved in disease pathways.

2. Disease Network Analysis

- Diseases are often caused by disruptions in biological networks, such as gene regulatory networks or protein-protein interaction networks. In network pharmacology, disease-associated genes, proteins, or pathways are identified, and drugs that modulate these networks are assessed for their potential efficacy in treating the disease.

3. Integrating 'Omics' Data

- Network pharmacology often combines various layers of 'omics' data (genomics, proteomics, transcriptomics) to gain a deeper understanding of how drugs influence cellular processes. By studying gene expression or protein activity in response to a drug, one can predict novel therapeutic uses for existing drugs.

4. Polypharmacology

- One of the central principles of network pharmacology is polypharmacology—drugs can have multiple targets, and their effects depend on the collective action across these targets. This can lead to more effective treatments, particularly for complex diseases like cancer, neurodegenerative diseases, or cardiovascular conditions.

5. Drug Repurposing via Network Pharmacology

- In the context of drug repurposing, network pharmacology can identify whether existing drugs might have hidden benefits for different diseases. By analyzing how drugs interact with disease-related networks, it's possible to propose new indications for approved drugs.

6. Predictive Modeling & Computational Tools

- A variety of computational approaches, such as network-based algorithms, machine learning, and molecular docking, are used to predict how drugs will interact with biological networks. Tools like Cytoscape and others can visualize and analyze these networks.

Machine Learning and Artificial Intelligence

1. Predictive Modeling for Drug Repurposing

- **Machine learning algorithms** can analyze vast amounts of data from biological experiments, clinical trials, and molecular databases to predict new drug-disease associations. By training models on existing data, ML can uncover patterns and relationships that might not be immediately obvious.
- **Supervised learning** techniques, such as regression or classification, can predict whether a drug might be effective for a new disease based on features like chemical structure, target proteins, or gene expression profiles.
- **Unsupervised learning**, such as clustering, can group drugs or diseases with similar characteristics, suggesting novel repurposing opportunities.

2. AI in Drug Target Prediction

- **AI models** are capable of predicting potential drug targets by analyzing large datasets of protein-protein interactions, gene expression data, and known drug-target interactions. These models can be trained to identify novel biological targets that are associated with specific diseases, thereby suggesting existing drugs that could interact with these targets.
- **Deep learning**, a subset of AI, has gained significant attention for its ability to learn hierarchical representations of data. In drug discovery, deep learning models can predict interactions between drugs and multiple targets or proteins, potentially revealing new therapeutic avenues.

3. Chemoinformatics and Drug Screening

- **Chemoinformatics** is the use of computational techniques to analyze chemical structures. ML algorithms can be used to analyze compound libraries and identify candidates that are likely to be effective for a given disease.
- **Virtual screening** with AI and ML models can help simulate how existing drugs might bind to new targets or affect biological processes. By evaluating millions of compounds in silico, researchers can prioritize candidates for further testing.

4. Data Integration for Drug Repurposing

- AI and ML are instrumental in integrating diverse types of data, such as genomic, transcriptomic, proteomic, and clinical data. For instance, **multi-omics data integration** enables the development of comprehensive models that consider various biological factors and drug interactions, improving the ability to repurpose existing drugs for new indications.
- These techniques help create predictive models that can highlight drugs with potential efficacy for diseases that lack effective treatments, speeding up the repurposing process.

5. Network Pharmacology and AI

- **AI-based algorithms** can model complex drug-target networks and predict how drugs interact with biological networks. These tools can identify key molecular nodes and pathways that may be impacted by a drug, which is crucial for understanding polypharmacology and predicting drug efficacy in treating multiple diseases.
- **Graph neural networks** (GNNs) and other advanced AI methods are used to model and analyze network-based pharmacology, where nodes represent drugs or biological molecules, and edges represent interactions between them.

6. AI for Personalized Medicine

- In drug repurposing, AI can help identify subgroups of patients who might benefit from repurposed drugs. By analyzing patient data, such as genetic profiles, medical

history, and response to treatment, AI can predict which patients are more likely to respond to a particular drug, thus improving treatment outcomes and reducing side effects.

7. Natural Language Processing (NLP) for Drug Repurposing

- **NLP techniques** are used to mine scientific literature, clinical records, patents, and other unstructured text data to uncover drug repurposing opportunities. AI models can read and extract relevant information from vast amounts of text, identifying drug-disease relationships that might otherwise be overlooked.

8. AI-Driven Experimental Design

- **Reinforcement learning** and other AI techniques are used to optimize experimental design in drug testing. By learning from previous experiments, AI can suggest the most promising experimental setups, improving the efficiency and speed of testing drug repurposing hypotheses.

9. Examples of AI and ML Tools in Drug Repurposing:

- **DeepChem**: A library for deep learning in drug discovery, which facilitates training models on chemical and biological data for tasks such as predicting molecular properties and drug-target interactions.
- **AlphaFold**: An AI system developed by DeepMind that predicts protein structures with high accuracy, helping to understand drug-target interactions better.
- **RepurposeDB**: A database of drug repurposing opportunities, which uses AI and data mining techniques to identify and predict new indications for existing drugs.

10. Challenges and Future Directions

- **Data quality and availability**: The effectiveness of AI/ML models relies on large, high-quality datasets. Incomplete or biased data can lead to incorrect predictions.
- **Interpretability**: Many AI models, especially deep learning models, are complex and can act as "black boxes," making it difficult to interpret the biological mechanisms behind predictions.
- **Regulatory and ethical considerations**: AI models in drug repurposing must meet stringent regulatory requirements, and there are ethical concerns regarding privacy and data usage, particularly in clinical trials.

11. Collaborative Efforts

- Collaborative initiatives, such as the National Center for Advancing Translational Sciences (NCATS) Drug Repurposing Program, bring together researchers, industry, and regulatory agencies to accelerate repurposing efforts. These collaborations facilitate data sharing, resource pooling, and the development of standardized methodologies.

Discussion

Drug repurposing represents a promising strategy for addressing unmet medical needs and accelerating drug development. By leveraging existing knowledge and resources, this approach offers a cost-effective and time-efficient alternative to traditional drug discovery. However, realizing the full potential of drug repurposing requires addressing several challenges, including intellectual property issues, regulatory hurdles, and scientific complexity.

Collaborative efforts and innovative technologies are essential for advancing the field. Initiatives such as the NCATS Drug Repurposing Program and the Repurposing Drugs in Oncology (ReDO) project demonstrate the value of data sharing and resource pooling. Moreover, advances in computational biology, artificial intelligence, and high-throughput screening are enabling the systematic identification of repurposing opportunities.

The COVID-19 pandemic has highlighted the potential of drug repurposing in rapidly identifying treatments for emerging diseases. However, it has also underscored the importance of rigorous scientific evaluation and regulatory oversight. While some repurposed drugs, such as dexamethasone, have shown promise, others, such as hydroxychloroquine, have not demonstrated efficacy and have raised safety concerns.

Future directions in drug repurposing include the integration of multi-omics data, the development of predictive models, and the exploration of combination therapies. Additionally, patient-centered approaches, such as personalized medicine and real-world evidence, are likely to play an increasingly important role in identifying and validating repurposing opportunities.

Table 1: Comparison of Traditional Drug Discovery vs. Drug Repurposing

Aspect	Traditional Drug Discovery	Drug Repurposing
Time	10-15 years	3-5 years
Cost	$2-3 billion	$300-500 million
Success Rate	<10%	~30%
Regulatory Hurdles	Extensive	Streamlined
Intellectual Property	Strong patent protection	Limited patent protection

Table 2: Emerging Drug Repurposing Opportunities

Drug	Original Indication	New Indication	Stage of Development
Metformin	Type 2 Diabetes	Cancer	Phase III Clinical Trials
Propranolol	Hypertension	Hemangiomas, PTSD	Phase II Clinical Trials
Chloroquine	Malaria	COVID-19	Investigational
Hydroxychloroquine	Malaria, Autoimmune Diseases	COVID-19	Investigational

Conclusion

Drug repurposing offers a powerful strategy for addressing unmet medical needs and accelerating drug development. By leveraging existing knowledge and resources, this approach

has the potential to transform drug discovery and improve patient outcomes. However, realizing the full potential of drug repurposing requires addressing several challenges, including intellectual property issues, regulatory hurdles, and scientific complexity.

Collaborative efforts and innovative technologies are essential for advancing the field. The integration of multi-omics data, the development of predictive models, and the exploration of combination therapies are likely to drive future progress. Moreover, patient-centered approaches, such as personalized medicine and real-world evidence, are expected to play an increasingly important role in identifying and validating repurposing opportunities.

As the field continues to evolve, drug repurposing has the potential to make a significant impact on global health, particularly in addressing rare diseases, antimicrobial resistance, and emerging infectious diseases. By fostering collaboration and innovation, we can unlock the full potential of drug repurposing and improve the lives of patients worldwide.

Acknowledgements

The authors would like to acknowledge the contributions of researchers, clinicians, and industry partners who have advanced the field of drug repurposing. Special thanks to the National Center for Advancing Translational Sciences (NCATS) and the Repurposing Drugs in Oncology (ReDO) project for their support and collaboration.

References

1. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery. 2004;3(8):673–83.
2. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery. 2019;18(1):41–58.
3. Oprea TI, Overington JP. Computational and practical aspects of drug repositioning. Assay and Drug Development Technologies. 2015;13(6):299–306.
4. Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534(7607):314–6.
5. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. The Repurposing Drugs in Oncology (ReDO) project. ecancermedicalscience. 2014;8:442.
6. National Center for Advancing Translational Sciences (NCATS). Drug Repurposing Program [Internet]; c2021 [cited 2025 Jan 29]. Available from: https://ncats.nih.gov/drug-repurposing
7. World Health Organization (WHO). COVID-19: Landscape of novel coronavirus candidate vaccine development worldwide [Internet]; c2020 [cited 2025 Jan 29]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
8. Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Briefings in Bioinformatics. 2011;12(4):303–11.
9. Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discovery Today. 2014;19(5):637–44.
10. Li J, Zheng S. Drug repositioning for personalized medicine. Genome Medicine. 2016;8(1):1–3.
11. Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharmaceutical Medicine. 2010;24(3):151–9.
12. Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS Journal. 2012;14(4):759–63.
13. Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z. A survey of current trends in computational drug repositioning. Briefings in Bioinformatics. 2016;17(1):2–12.
14. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nature Medicine. 2017;23(4):405–8.
15. Parvathaneni V, Gupta V. Utilizing drug repurposing against COVID-19–Efficacy, limitations, and challenges. Life Sciences. 2020;259:118275.
16. Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. Journal of Pharmacy and Pharmacology. 2020;72(9):1145–51.
17. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, et al. A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery. 2017;16(1):19–34.
18. Mullard A. Drug repurposing programmes get lift off. Nature Reviews Drug Discovery. 2015 Aug;14(8):441–2.
19. Mittal N, Mittal R. Repurposing old molecules for new indications: defining pillars of success from lessons in the past. European Journal of Pharmacology. 2021;912:174569.
20. Mishra AS, Vasanthan M, Malliappan SP. Drug repurposing: a leading strategy for new threats and targets. ACS Pharmacology & Translational Science. 2024;7(4):915–32.
21. Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology—patient and health systems opportunities. Nature Reviews Clinical Oncology. 2015;12(12):732–42.
22. Corsello SM, Stegmaier K. Targeting oncogenic dependencies in cancer with small molecules. Nature Reviews Cancer. 2015;15(7):442–55.
23. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. International Journal of Biological Sciences. 2014;10(7):654–63.
24. Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. Pharmacological Research. 2017;124:74–91.
25. Antibiotics, antivirals and vaccines could help tackle dementia, study suggests. The Guardian [Internet]; c2025 [cited 2025 Jan 29].
26. The prescription drugs that slash dementia risk revealed—those that could raise it, from high blood pressure to diabetes. The Scottish Sun [Internet]; c2025 [cited 2025 Jan 29].
27. Deshalb können Nebenwirkungen nützlich sein. Die Welt [Internet]; c2024 [cited 2025 Jan 29].
28. Weight-loss drugs ‘could be used to treat Alzheimer’s disease’. The Times [Internet]; c2024 [cited 2025 Jan 29].
29. Type 2 diabetes drug associated with 35% lower risk of dementia, study finds. The Guardian [Internet]; c2024 [cited 2025 Jan 29].